PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin

Oncogenesis

Volumn 1, Issue 7, 2012, Pages

  Lee, J ^a   Bartholomeusz, C ^a   Krishnamurthy, S ^a   Liu, P ^a   Saso, H ^a   Lafortune, T A ^a   Hortobagyi, G N ^a   Ueno, N T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

b catenin; growth inhibition; ovarian cancer; PEA 15; three dimensional Matrigel cultures; tumorigenicity

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; BETA CATENIN; PEA 15; SERINE; SERINE 104; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENICITY; CELL MIGRATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MUTANT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

PISUM SATIVUM;

EID: 84868282628     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.22     Document Type: Article

References (51)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Renault F, Formstecher E, Callebaut I, Junier MP, Chneiweiss H. The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes. Biochem Pharmacol 2003; 66: 1581-1588. (Pubitemid 38373349)
3. Glading A, Koziol JA, Krueger J, Ginsberg MH. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res 2007; 67: 1536-1544. (Pubitemid 46383377)
4. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 2006; 25: 79-90. (Pubitemid 43050006)
5. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T et al. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 2008; 68: 9302-9310.
6. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX et al. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 2010; 16: 1802-1811.
7. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11: 3286-3305. (Pubitemid 28023954)
8. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790. (Pubitemid 27136715)
9. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR et al. Association of the APC gene product with beta-catenin. Science 1993; 262: 1731-1734. (Pubitemid 24030096)
10. Morin PJ. beta-catenin signaling and cancer. Bioessays 1999; 21: 1021-1030.
11. Jin T, George Fantus I, Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal 2008; 20: 1697-1704.
12. Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 2008; 149: 2341-2351. (Pubitemid 351574509)
13. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126: 955-968. (Pubitemid 44310775)
14. Choo AY, Roux PP, Blenis J. Mind the GAP: Wnt steps onto the mTORC1 train. Cell 2006; 126: 834-836. (Pubitemid 44310790)
15. Fiory F, Formisano P, Perruolo G, Beguinot F. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. Am J Physiol Endocrinol Metab 2009; 297: E592-E601.
16. Krueger J, Chou FL, Glading A, Schaefer E, Ginsberg MH. Phosphorylation of phosphoprotein enriched in astrocytes (PEA-15) regulates extracellular signalregulated kinase-dependent transcription and cell proliferation. Mol Biol Cell 2005; 16: 3552-3561. (Pubitemid 41077069)
17. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993; 53: 891-898. (Pubitemid 23077880)
18. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84-96. (Pubitemid 46776616)
19. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981.
20. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512. (Pubitemid 28425575)
21. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426. (Pubitemid 29180374)
22. Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, Shedden KA et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003; 63: 2913-2922. (Pubitemid 36667164)
23. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003; 63: 728-734. (Pubitemid 36158154)
24. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000; 97: 14608-14613. (Pubitemid 32016623)
25. Chou FL, Hill JM, Hsieh JC, Pouyssegur J, Brunet A, Glading A et al. PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. J Biol Chem 2003; 278: 52587-52597. (Pubitemid 38035856)
26. Formstecher E, Ramos JW, Fauquet M, Calderwood DA, Hsieh JC, Canton B et al. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell 2001; 1: 239-250. (Pubitemid 33653059)
27. Hill JM, Vaidyanathan H, Ramos JW, Ginsberg MH, Werner MH. Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain. EMBO J 2002; 21: 6494-6504. (Pubitemid 35448427)
28. Whitehurst AW, Robinson FL, Moore MS, Cobb MH. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. J Biol Chem 2004; 279: 12840-12847. (Pubitemid 38445857)
29. Renganathan H, Vaidyanathan H, Knapinska A, Ramos JW. Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD. Biochem J 2005; 390: 729-735. (Pubitemid 41395356)
30. Trencia A, Perfetti A, Cassese A, Vigliotta G, Miele C, Oriente F et al. Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol Cell Biol 2003; 23: 4511-4521. (Pubitemid 36734742)
31. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001; 294: 1708-1712. (Pubitemid 33104840)
32. Formisano P, Ragno P, Pesapane A, Alfano D, Alberobello AT, Rea VE et al. PED/PEA-15 interacts with the 67 kDa laminin receptor and regulates cell adhesion, migration, proliferation and apoptosis. J Cell Mol Med 2012; 16: 1435-1446.
33. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-847. (Pubitemid 34327534)
34. Bienz M. beta-Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 2005; 15: R64-R67.
35. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 1443-1454. (Pubitemid 26260702)
36. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789. (Pubitemid 26004411)
37. Hino S, Tanji C, Nakayama KI, Kikuchi A. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol 2005; 25: 9063-9072. (Pubitemid 41429094)
38. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006; 281: 9971-9976. (Pubitemid 43864529)
39. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007; 282: 11221-11229. (Pubitemid 47100795)
40. He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007; 39: 189-198. (Pubitemid 46184349)
41. Cheadle C, Nesterova M, Watkins T, Barnes KC, Hall JC, Rosen A et al. Regulatory subunits of PKA define an axis of cellular proliferation/ differentiation in ovarian cancer cells. BMC Med Genomics 2008; 1: 43.
42. This is a list of target genes of Wnt/beta-catenin signaling. Updated December 2009; Available from http://www.stanford.edu/Brnusse/pathways/targets. html.
43. Rosano L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 2005; 65: 11649-11657. (Pubitemid 41821725)
44. Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer 2009; 19: 992-997.
45. Skurk C, Maatz H, Rocnik E, Bialik A, Force T, Walsh K. Glycogen-synthase kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res 2005; 96: 308-318. (Pubitemid 40279905)
46. Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol 2010; 27: 1246-1253.
47. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006; 231: 20-27. (Pubitemid 43063974)
48. Ramos JW, Kojima TK, Hughes PE, Fenczik CA, Ginsberg MH. The death effector domain of PEA-15 is involved in its regulation of integrin activation. J Biol Chem 1998; 273: 33897-33900. (Pubitemid 29008850)
49. Ramos JW, Hughes PE, Renshaw MW, Schwartz MA, Formstecher E, Chneiweiss H et al. Death effector domain protein PEA-15 potentiates Ras activation of extracellular signal receptor-activated kinase by an adhesion-independent mechanism. Mol Biol Cell 2000; 11: 2863-2872. (Pubitemid 32107070)
50. Bock BC, Tagscherer KE, Fassl A, Kramer A, Oehme I, Zentgraf HW et al. The PEA-15 protein regulates autophagy via activation of JNK. J Biol Chem 2010; 285: 21644-21654.
51. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4: 359-365. (Pubitemid 46766981)